A Purdue Pharma affiliate has expanded abroad, selling addictive opioids using some of the tactics that made its owners among the world's richest. From Europe to Australia, Mundipharma also aims to dominate the opioid overdose treatment market.
This undated image provided by Dr. Andrew Kolodny shows Purdue Pharma’s international affiliate, Mundipharma, promoting Nyxoid, a new brand of opioid overdose reversal medication, at a medical conference in Italy. The photo was taken by Kolodny, a frequent critic of Purdue Pharma who has testified against the company.
“The way that they’ve pushed their opioids initially and now coming up with the expensive kind of antidote -- it’s something that just strikes me as deeply, deeply cynical,” said Ross Bell, executive director of the New Zealand Drug Foundation and a longtime advocate of greater naloxone availability. “You’ve got families devastated by this, and a company who sees dollar signs flashing.
In internal documents, the lawsuits allege, Purdue illustrated the connection they had publicly denied between opioids and addiction with a graphic of a blue funnel. The top end was labeled “Pain treatment.” The bottom: “opioid addiction treatment.” The slideshow said they had an opportunity to become an “end-to-end provider” — opioids on the front end, and addiction treatment on the back end.
Project Tango stalled. It was revised the next year with a new plan to sell naloxone, the lawsuits allege. In the document, the company suggested that officials change the country’s laws to allow for easier access to naloxone, get naloxone into needle exchange programs, detox centers and supervised injecting clinics, and establish a national, free take-home naloxone program.
Mundipharma also paid for a drug policy institute’s study on naloxone that the federal government ultimately used as a blueprint for a 10 million Australian dollar pilot program to distribute naloxone, including Nyxoid. And in October, Australian Health Minister Greg Hunt announced that Australia’s government would subsidize Nyxoid prescriptions, meaning it costs Australians as little as AU$6.50 per pack, versus around AU$50 without the subsidy.
Grand, the spokesman for Mundipharma Europe, also rejected any link between the company’s Nyxoid strategy and Project Tango, saying that the European company and Purdue have separate managements, boards and strategies.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Fate of global climate action 'in the balance' as U.N. talks go down to wireBig polluting countries faced last-ditch pressure from smaller nations on Friday...
Read more »
Far from U.S. epidemic, ‘the other opioid crisis’ rages in vulnerable countries'`Safer opioid’ has sparked a crisis in vulnerable countries
Read more »
Fate of global climate action 'in the balance' as UN talks go down to wireWith the two-week gathering mired in interlocking disputes over how to implement the 2015 Paris Agreement on global warming, Chile, presiding over the talks, had earlier attempted to inject a note of optimism.
Read more »
A Chilean Feminist Anthem Decrying Gender Violence Goes Global“Un violador en tu camino” ('A Rapist in Your Path') was created by Chilean art collective Lastesis to highlight gender-based violence and rape in the country. The song is inspiring pop-up performances around the world. hereandnow
Read more »
Another opioid crisis is raging through the developing worldKAPURTHALA, India (AP) — Reports rolled in with escalating urgency — pills seized by the truckload, pills swallowed by schoolchildren, pills in the pockets of dead terrorists. These pills,...
Read more »